Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal

3150 - Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142

Date

10 Sep 2017

Session

Gastrointestinal tumours, colorectal

Presenters

Thierry André

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

T. André1, M. Overman2, S. Lonardi3, M. Aglietta4, R. McDermott5, K.Y.M. Wong6, M. Morse7, A. Hendlisz8, R.A. Moss9, J. Ledeine10, H. Tang11, Z..A. Cao9, S. Kopetz12

Author affiliations

  • 1 Medical Oncology, Hopital Saint Antoine, 75571 - Paris/FR
  • 2 Gastrointestinal (gi) Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Medical Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 4 Division Of Medical Oncology, Department Of Oncological Sciences, Institute for Cancer Research and Treatment, Candiolo and University of Torino Medical School, Turin/IT
  • 5 Medical Oncology, St. Vincent’s University Hospital, 24 - Dublin/IE
  • 6 Medical Oncology, The University of Sydney, Sydney Medical School, Sydney/AU
  • 7 Department Of Surgery, Duke University Office of Research Administration, Durham/US
  • 8 Gastroenterology, Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 9 Research And Development, Bristol-Myers Squibb, Princeton/US
  • 10 Research And Development, Bristol-Myers Squibb, Braine-L’Alleud/BE
  • 11 Research And Development, ristol-Myers Squibb, Princeton/US
  • 12 Gi Medical Oncology, MD Anderson Cancer Center, Houston/US
More

Resources

Abstract 3150

Background

In the CheckMate 142 trial (NCT02060188), NIVO + IPI demonstrated manageable safety and clinical activity characterized by an investigator-assessed objective response rate (ORR) of 55%, disease control rate (DCR; defined as CR + PR + SD ≥ 12 wk) of 79%, and encouraging survival benefit (6-mo PFS and OS rates:77% and 89%) in pts with dMMR/MSI-H mCRC (Andre T, et al. ASCO 2017). Here, we report biomarker analyses in pts who received NIVO + IPI in the CheckMate 142 study.

Methods

Pts with dMMR/MSI-H mCRC who progressed on or were intolerant of ≥ 1 prior line of therapy received NIVO 3 mg/kg + IPI 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W. Tumor anti-programmed death ligand 1 (PD-L1) expression was assessed using the Dako 28-8 pharmDx assay. PD-L1 positivity was defined as ≥ 1% cell membrane staining of any intensity. BRAF and KRAS mutation statuses were determined by investigators per local guidelines. Characterization of Lynch syndrome as present or absent was based on past medical history from clinical records. ORR per investigator was determined per RECIST v1.1.

Results

Tumor PD-L1 expression and BRAF/KRAS statuses were assessed in 84 pts. ORR and DCR by PD-L1, BRAF/KRAS mutational status, and clinical history of Lynch syndrome are reported in the Table below.

Conclusions

Confirmed responses with NIVO + IPI were observed in pts with dMMR/MSI-H mCRC who were PD-L1 expressors and non-expressors, as well as across BRAF and KRAS mutational status. Responses were also observed in pts with or without a history of Lynch syndrome. These results are consistent with previously reported biomarker analyses of the NIVO monotherapy cohort.Table:

484PD

Pts, n (%) [95%CI]dMMR/MSI-H mCRC N = 84 Pts With ≥ 6 Mo of Follow-Up
ORRDCR
Tumor PD-L1 expression*
≥1% (n = 16)9 (56) [29.88, 80.25]12 (75) [47.62, 92.73]

Clinical trial identification

Clinical Protocol CA209142. The release date 18-Nov-2013.

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

T. André: Personal fees: Bristol-Myers Squibb, Roche, Servier, Baxter, Novartis, MSD, Amgen, Lilly, Sanofi, Halliodx, Xbotech and Boehringer Ingelheim. Non-financial support: Roche and BMS. M. Overman: Grantes and personal fees from BMS, outside the submitted work. S. Lonardi: Personal Fees: Amgen; Bayer; Lilly; Roche and Sanofi. M. Aglietta: Advisory board with BMS. R. McDermott: Personal fees: Clovis, Pfizer, and BMS; research funding from Merck, BMS, Janssen, and Bayer; grants from Pfizer, Celgene, and Amgen outside the submitted work. K.Y.M. Wong: Other from BMS, during the conduct of the study. M. Morse: Grants from BMS, during the conduct of the study. R.A. Moss: Employee and stock holder of BMS. J-M. Ledeine: Personal fees from Bristol-Myers Squibb, during the conduct of the study. H. Tang: Employee of BMS. Z.A. Cao: Employee of BMS and a stockholder of BMS and Novartis. S. Kopetz: Consulting/Advisor roles: Amgen, Array BioPharma, Bayer, BMS, Genentech, GSK, Janssen, Merrimack, MolecularMatch, Oculose LLC, Roche, Sanofi, Sirtex Medical, Taiho Pharmaceutical, Rsch Funding-Agendia, Amgen, Biocartis, GSK, Guardant Health, Roche, Sanofi, Sysmex; other: MolecularMatch. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.